Gaithersburg, MD, January 16, 2017 – MaxCyte®, Inc., developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced today that Madhusudan V.
Released : January 12, 2017 07:00 RNS Number : 9615T MaxCyte, Inc. 12 January 2017 MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 X-Linked CGD Gene Repair - MaxCyte's Proprietary GT® System fosters translational development of ex
Released : January 03, 2017 14:49 RNS Number : 2281T MaxCyte, Inc. 03 January 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Issue of Equity from exercise of Share Options Maryland, USA -03 January 2017: MaxCyte (LSE: MXCT) announces the issue and allotment of 18,293 new shares of
Released : December 21, 2016 07:00 RNS Number : 4115S MaxCyte, Inc. 21 December 2016 MaxCyte Announces Collaboration to Further Advance CARMA - Preclinical research to focus on developing therapies based on MaxCyte's proprietary CARMA platform - CARMA has potential for broad
Preclinical research to focus on developing therapies based on MaxCyte’s proprietary CARMA platform – CARMA has potential for broad applicability against solid or liquid tumor indications Gaithersburg, MD, December 21, 2016 – MaxCyte®, Inc. today announces a strategic collaboration with
Released : December 06, 2016 09:34 RNS Number : 0823R MaxCyte, Inc. 06 December 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Issue of Equity from exercise of Share Options Maryland, USA - 06 December 2016: MaxCyte (LSE: MXCT), announces the issue and allotment of 12,805 new
Biotech industry veteran to lead alliance-building efforts for MaxCyte’s proprietary CARMA platform Gaithersburg, Maryland – November 2, 2016 – MaxCyte, Inc., a developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and
Released : October 27, 2016 07:00 RNS Number : 5694N MaxCyte, Inc. 27 October 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of Annual General Meeting Maryland, USA - 27 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based
Released : October 21, 2016 07:43 RNS Number : 1438N MaxCyte, Inc. 21 October 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Driector/PDMR Sharedealing Maryland, USA - 21 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines,
Gaithersburg, MD, 29 September 2016 – MaxCyte®, Inc., an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and
